Zobrazeno 1 - 5 of 5 pro vyhledávání: '"Erzsébet Juhász"'
1
Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy
Autor: Garry Alan Weems, Karen Kelly, Erzsébet Juhász, Jyoti D. Patel, Christopher G. Azzoli, Peter Y.Z. Jiang, Nicholas Iannotti, Petr Zatloukal, José Rodrigues Pereira, David Bodkin, Istvan Albert, Tony Koutsoukos
Publikováno v: Journal of Thoracic Oncology. 7:1041-1048
Introduction Pralatrexate, a folate analogue targeting dihydrofolate reductase, has antitumor activity in non–small-cell lung cancer (NSCLC). This randomized phase 2b trial was designed to further evaluate pralatrexate activity in NSCLC by estimati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8588e5c7aa858dafbe60a22f9d43cee7
https://doi.org/10.1097/jto.0b013e31824cc66c
Zobrazit plný text záznamu
2
Cisplatin–vinorelbine chemotherapy in non-small cell lung cancer is safe and well tolerated: results of a retrospective Hungarian clinical data analysis
Autor: Lilla Tamási, Pál Magyar, Erzsébet Juhász, Veronika Müller, Marianna Budai, Mária Szilasi
Publikováno v: Expert Opinion on Drug Safety. 8:9-14
The efficacy of cisplatin-vinorelbine chemotherapy (CT) in NSCLC is well established. In this retrospective data analysis, haematological safety and tolerability, furthermore the effects of cisplatin-vinorelbine combination on patients' quality of li
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2048c2971a2b4dc240cc601b8dbec3c0
https://doi.org/10.1517/14740330802521771
Zobrazit plný text záznamu
3
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
Autor: Jean-Louis Pujol, Jerzy Kozielski, Lukas C. Amler, Nigel Baker, Petr Zatloukal, Avi Ashkenazi, Yang Pan, Yong Jiang Hei, Fiona H Blackhall, Istvan Albert, Jean-Charles Soria, Barna Szima, D. Smethurst, Erzsébet Juhász, Howard M. Stern, Zsuzsanna Mark
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(33)
Purpose To evaluate the efficacy and safety of dulanermin combined with paclitaxel and carboplatin (PC) and bevacizumab (PCB) as first-line treatment for advanced or recurrent non–small-cell lung cancer (NSCLC). Patients and Methods Patients with s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c867223b8bb2a811bbe405ab28df8537
https://pubmed.ncbi.nlm.nih.gov/22010015
Zobrazit plný text záznamu
4
TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study
Autor: Erzsébet Juhász, Thaddeus Beck, Jean-Marc Limacher, Helen J. Ross, Anton Melnyk, Zsuzsanna Mark, Rosa Alvarez, Joseph Potz, Arnaud Scherpereel, Lecia V. Sequist, Jean-Philippe Oster, Elisabeth Quoix, Nandagopal Vrindavanam, John Nemunaitis, Piotr Jaskiewicz, Saiama N. Waqar
Publikováno v: Journal for Immunotherapy of Cancer
Meeting abstracts TG4010 immunotherapy product is a poxvirus (MVA) coding for MUC1 tumor-associated antigen and interleukin-2. A previous study showed that a normal baseline level of Triple Positive Activated Lymphocytes (TrPAL, CD16+CD56+CD69+) migh
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b44054eb9b4d7a1e3a215ce3a1786bc
http://europepmc.org/articles/PMC4288318
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje